Sigachi’s Big Pharma Power Move: New API Facility to Dominate Global Markets!

Unknown Apr 02, 2026 1,000 Views

Sigachi Industries Ltd. is making bold strides in the pharmaceutical sector with its latest project aimed at enhancing API manufacturing capacity and expanding its global footprint. The company has received Terms of Reference (ToR) for a new facility, signaling a major step toward strengtheni...

Key Highlights:

- Capacity Expansion: Sigachi is ramping up production with a new API facility, expected to significantly increase output and efficiency.

- Strategic Growth: The company aims to penetrate new international markets, leveraging its expertise in excipients and pharmaceutical solutions.

- Regulatory Approvals: With the ToR in place, Sigachi is set to fast-track environmental and operational clearances for the facility.

- Market Leadership: Already a top global manufacturer of microcrystalline cellulose (MCC), Sigachi is now diversifying into APIs to strengthen its pharmaceutical portfolio.

- Revenue Surge: The company reported a 25% YoY revenue growth, driven by capacity expansions and market diversification.

Sigachi’s aggressive expansion strategy positions it as a key player in the global pharmaceutical supply chain, with its new API facility expected to fuel long-term growth and innovation.

Sources: Sigachi Industries Investor Presentation, The CEO Magazine, DNB India.

Sources: Sigachi Industries Investor Presentation, The CEO Magazine, DNB India.Sigachi Industries Ltd. is making bold strides in the pharmaceutical sector with its latest project aimed at enhancing API manufacturing capacity and expanding its global footprint. The company has received Terms of Reference (ToR) for a new facility, signaling a major step toward strengthening its presence in the high-value Active Pharmaceutical Ingredients (API) market.

Key Highlights:

- Capacity Expansion: Sigachi is ramping up production with a new API facility, expected to significantly increase output and efficiency.

- Strategic Growth: The company aims to penetrate new international markets, leveraging its expertise in excipients and pharmaceutical solutions.

- Regulatory Approvals: With the ToR in place, Sigachi is set to fast-track environmental and operational clearances for the facility.

- Market Leadership: Already a top global manufacturer of microcrystalline cellulose (MCC), Sigachi is now diversifying into APIs to strengthen its pharmaceutical portfolio.

- Revenue Surge: The company reported a 25% YoY revenue growth, driven by capacity expansions and market diversification.

Sigachi’s aggressive expansion strategy positions it as a key player in the global pharmaceutical supply chain, with its new API facility expected to fuel long-term growth and innovation.

Sources: Sigachi Industries Investor Presentation, The CEO Magazine, DNB India.

Stay Ahead – Explore Now! Noida International Airport Commences Commercial Flight Operations